Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
Increased Cancer Risk: Some contaminants or impurities in unregulated peptides could have carcinogenic properties, potentially increasing the risk of cancer with long-term use
Not dosing advice and not for human or animal administration
ICD-10 Codes for Folate Deficiency Anemia: D52 D52.0: Dietary folate deficiency anemia D52.1: Drug-induced folate deficiency anemia D52.8: Other folate deficiency anemias D52.9: Folate deficiency anemia, unspecified Other Nutritional Anemias Nutritional anemias occur when patients face a shortage of minerals and vitamins required to produce red blood cells
